 CAMBRIDGE, Mass., Sept. 08, 2021 GLOBE NEWSWIRE -- Werewolf Therapeutics, Inc. Nasdaq: HOWL, an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15. 